Your audience leaves having found something in their own organisation
Most conference talks on sustainability and decision-making restate what the audience already believes. Mine opens with a claim that unsettles them. a company can meet every sustainability reporting obligation it has and still fund the portfolio it would have funded anyway. Then it proves it.
The proof is published, peer-reviewed and checkable. The exercise that follows runs on the audience’s own targets, not a case study. People leave having found something in their own organisation.
18years in pharmaceutical development
23peer-reviewed publications
250+members in the group I chair
447stakeholders in my survey
Four talks, each with a named audience
The target that cannot bind youWhy a limit set against your own performance can never require improvement, the three conditions that make it true, and a live check on targets the audience has already published. The strongest room-changer, and the one I would recommend for a mixed or board audience.
Where a criterion actually enters a decisionThe Three Gates: scoring, weighting, eligibility. Why the argument about weights so often changes nothing, and which gate is quietly doing the deciding in your governance.
Estimands that survive a regulatorWhat ICH E9(R1) asks and how to choose an estimand you can defend, from a co-author of the three practice papers the industry uses. For statistical and clinical development audiences.
Why good frameworks get abandonedWhat happens to a decision framework under time pressure, drawn from embedding a Probability of Success framework across a large development organisation. For leadership and governance audiences.
Each can be tailored to your sector or your agenda. I will say plainly if a topic is outside what I can evidence.
Four formats, from twenty minutes to half a day
20–45 minConference keynote or session talkOne idea, the evidence behind it, and the limits stated. Q&A included.
60–90 minBoard or leadership sessionBuilt around a decision you are actually facing. Material reviewed with you beforehand.
Half dayWorking sessionThe room runs the three questions on its own published targets and leaves with a written result.
PanelsChairing and panel contributionI have chaired sessions at PharmaDS and run subteams across a 250-member working group.
Fees depend on format, preparation and travel. Academic, non-profit and early-career events are charged differently, and sometimes not at all. Ask. Travel from Basel; remote delivery available for any format.
Chaired at PharmaDS, taught at UCSF-Stanford CERSI
2024Co-Chair, Generative AI sessionPharmaDS, New England Statistical Society
RecurringInstructor, Bayesian Thinking in Clinical ResearchUCSF–Stanford Center of Excellence in Regulatory Science and Innovation
VariousInvited presentations on decentralised and sustainable trial designIncluding DIA conferences
2017 —Bayesian Scientific Working Group, ASA Biopharmaceutical SectionChair since 2023, across eight subteams.
What organisers say
Everything you need to announce me, ready to copy
Short biography. Pritibha Singh researches how organisations allocate capital under uncertainty. Her doctorate at ETH Zurich examines where a sustainability criterion must enter a portfolio decision before it changes what gets funded. She brings eighteen years in pharmaceutical development, including a decade across Novartis and Sandoz, and chairs the Bayesian Scientific Working Group of the ASA Biopharmaceutical Section.
One-line introduction. „Pritibha Singh studies why carefully argued decisions so often come out the way they would have anyway.“
Practical. Delivered in English. Standard AV: projector or large screen, HDMI, and a lapel or handheld microphone for rooms over forty. I bring my own slides and a backup copy. Photograph and full speaker biography supplied on request.